Schnell & portofrei.
Alle Medien. Alle Verlage.

Zurück zur Trefferliste

Littman / Krishna

Translational Medicine and Drug Discovery

2011. Buch. ca. 344 S. Hardcover
Cambridge University Press ISBN 978-0-521-88645-1
Format (B x L): 21,5 x 25,3 cm
In englischer Sprache
This book, edited by two innovative leaders in the field, focuses on the new discipline of translational medicine as it pertains to drug development within the pharmaceutical and biotechnology industry. Translational medicine seeks to translate biological and molecular knowledge of disease and how drugs work into innovative development strategies that reduce the cost and increase the speed of delivering new medicines for patients. This book outlines general strategies, biomarker development, imaging tools, translational human models, and examples of their application to real drug development. The latest thinking is presented by researchers from many of the world's leading drug development companies, including Pfizer, Merck, Eli Lilly, Abbott, and Novartis, as well as academic institutions and public-private partnerships that support translational research. This book is essential for anyone interested in translational medicine from a variety of backgrounds: university institutes, medical schools, pharmaceutical companies, and drug development researchers and decision-makers.
lieferbar, ca. 4 Wochen
ca. 121,38 €
inkl. MwSt.
Bearbeitet von: link iconBruce H. Littman, Rajesh Krishna, PhD, FCP, is an area lead director in early stage development at Merck Research Laboratories. Dr Krishna is the editor of 3 books on new drug development besides publishing nearly over 120 articles and oral/poster presentations, Dr. Krishna has served as a section editor for the Journal of Clinical Pharmacology, associate editor for BMC Clinical Pharmacology, and an editorial board member for BMC Medicine. He is a Fellow of the American College of Clinical Pharmacology and the American Ass, link iconRajesh Krishna, Bruce Littman, MD, is the founder of Translational Medicine Associates, LLC, as well as former co-chair and current member of the Inflammation and Immunity Steering Committee of the Biomarker Consortium. Prior to starting his own company, Dr Littman was the Vice President and Global Head of Translation Medicine at Pfizer Inc. where he worked for 19 years, first in Experimental Medicine and then Translational Medicine. He was also a faculty member of Virginia Commonwealth University School of Medicine for